Recipharm AB publishes its interim report January-March 2018
January – March 2018 · Net sales amounted to SEK 1,513 million (1,328), an increase of 14% · EBITDA increased by 57% and amounted to SEK 250 million (159) corresponding to an EBITDA margin of 16.5% (12.0) · Operating profit (EBIT) amounted to SEK 120 million (46) · Profit after tax amounted to SEK 45 million (1) corresponding to a net margin of 3% (0) · Earnings per share amounted to SEK 0.70 (-0.04) before dilution and SEK 0.70 (-0.04) after dilution · Net debt to Equity was 0.8 (0.6) · Acquisition of the remaining 26% of Nitin Lifesciences Ltd Key figures